VCANBIO(SH:600645) Shang Hai Zheng Quan Bao·2025-12-25 18:48Group 1 - The company held its 24th temporary board meeting on December 25, 2025, where several resolutions were passed unanimously by the board members [1][2][4] - The company approved a proposal to postpone the investment project related to the development of tumor marker diagnostic reagents, extending the timeline to December 2026 [35][41] - The company appointed Mr. Zhang Yu as the co-president to enhance operational management efficiency in response to market challenges [2][9] - The company appointed Mr. Li Xu as the secretary of the board, ensuring compliance with relevant laws and regulations [5][10] Group 2 - The company plans to use up to RMB 1.2 billion of temporarily idle raised funds for cash management and up to RMB 600 million of idle self-owned funds for entrusted wealth management [22][24] - The company has a balance of RMB 159.87 million in raised funds as of December 15, 2025, with some funds temporarily idle due to project timelines [24][36] - The company will invest in low-risk, liquid principal-protected products and ensure that these investments do not affect the normal operations of the company [25][32] Group 3 - The company signed a termination agreement with the University of Chinese Academy of Sciences regarding the "Zhongyuan Xiehe Life Medicine Award," ceasing further donations after a total of RMB 7.8 million was contributed [11][12][19] - The termination of the donation agreement will not significantly impact the company's operations or financial status, as it seeks new partners for the award [19][41]